BioSpace News Archive

Semler Scientific, Inc. announced that its chief executive officer, Wayne T. Pan, Ph.D., M.D., and head of corporate communications and business strategy, Renae Cormier, will present a company overview at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, at 4:30 pm ET.

Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®) for use in patients with spinal cord injuries who rely on mechanical ventilation.

Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced that Eric Bjerkholt has been appointed to the Board of Directors.

Deka Biosciences (“Deka”), a clinical-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced today that the first subject has been dosed in a Phase 1 clinical trial of DK210 (EGFR) at NEXT Oncology in Fairfax, Virginia.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that its development partner Newsoara Biopharma Co. Ltd, has enrolled the first patient in its ongoing Phase 3 clinical trial in China.

Researchers at the Oak Crest Institute of Science have been exploring new ways to prevent the spread of HIV-1 among adolescent girls and young women in low and middle income countries, who are disproportionately affected by HIV-1.

Celularity Inc. announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 9,230,770 shares of its Class A common stock together with warrants to purchase up to 9,230,770 shares of its Class A common stock at a combined purchase price of $0.65 per share and accompanying warrant.

The Food Allergy Institute announced that a peer reviewed paper authored by its founder Inderpal Randhawa, MD, has been published by the clinical journal PLOS ONE.

ProSomnus, Inc. (“the Company”) (NASDAQ: OSA) today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent serial number (USPN) 11,617,677 on April 4, 2023, an addition to a portfolio of several issued U.S. patents covering the Company’s iterative titration technology featured in its FDA-cleared and patient-preferred Precision Oral Appliance Therapy (OAT) devices.

AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A)1 in patients with C9ORF72 amyotrophic lateral sclerosis (ALS)2.